Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

PAVS
Paranovus Entertainment Technology Ltd. Class A
stock NASDAQ

At Close
Jan 15, 2026 3:58:30 PM EST
2.02USD+13.202%(+0.24)520,557
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jan 15, 2026 9:27:30 AM EST
1.98USD+11.236%(+0.20)17,798
After-hours
Jan 15, 2026 4:48:30 PM EST
2.06USD+2.233%(+0.05)58,231
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrends
PAVS Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.
Take me to the API
PAVS Specific Mentions
As of Jan 16, 2026 3:36:21 AM EST (<1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
13 hr ago • u/Your_Answer_Is_No • r/pennystocks • the_lounge • C
What are everyone's thoughts on PAVS? Thinking of getting rid of it, but there's a lot of talk of a high SI. I just don't know if it's reported correctly with the RS recently
sentiment 0.00
15 hr ago • u/Difficult_Winner_777 • r/smallstreetbets • january_2026_squeeze_radar_list • Epic DD Analysis • B
In the spirit of the new year, I wanted to share with everyone a myriad portion of stocks on my radar for squeeze setups. Below I will list them with their respective links and some key details. This is not financial advice, this is just information. Always do your homework, nerds.
I originally posted this on short squeeze but I figured Id try something new.
In this List: DRMA, NFE, PAVS, AEHL, WOK, RPGL, SUGP. DRCT.
\-----------------------------------------------------------------------------------------------
# DRMA (Dermata Therapeutics Inc.):
[https://fintel.io/ss/us/drma](https://fintel.io/ss/us/drma)
Short Interest: 3,604.43% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 53.21% (source: FINRA);
Days to Cover: 8.87.
DRMA announced that its acne treatment XYNGARI achieved highly significant results in a Phase 3 trial, meeting all primary endpoints. Building on this momentum, management noted that the robust Phase 3 results have de-risked the upcoming second Phase 3 trial and position XYNGARI to potentially become the first oncwe-weekly topical acne treatment if approved. The company has also initiated discussions with potential partners for the Phase 3 program and eventual commercial rights to XYNGARI, signaling confidence in bringing this novel therapy to market.This was trailing above 100% just before the Jan12 data dump.
[https://www.nasdaq.com/market-activity/stocks/drma/short-interest](https://www.nasdaq.com/market-activity/stocks/drma/short-interest)
https://preview.redd.it/d30njg25ojdg1.jpg?width=1174&format=pjpg&auto=webp&s=634c324410ddbec3fee0da56970a3ad419c19808
https://preview.redd.it/82t7pvr5ojdg1.jpg?width=987&format=pjpg&auto=webp&s=b70e46779b97c4afe889126052fe5df2e7a51caf
\-----------------------------------------------------------------------------------------------
# NFE (New Fortress Energy Inc.):
[https://fintel.io/ss/us/nfe](https://fintel.io/ss/us/nfe)
Short Interest: 53.81 percent of float (source: NASDAQ)
Off-Exchange Short Volume Ratio: 51.93 percent (source: FINRA)
Days to Cover: 8.80
New Fortress Energy (NFE) is showing an elevated short interest profile with over 69 million shares short and a days-to-cover ratio nearing 9, suggesting shorts could be vulnerable to rapid covering pressure. The stock’s high off-exchange short volume further indicates non-transparent positioning that could unwind under a liquidity crunch. Additionally, NFE has maintained significant global LNG infrastructure exposure and recently secured final agreements for its offshore gas-to-power projects, which are expected to drive meaningful revenue growth over the next several quarters. These strategic expansions support long-term fundamentals while setting up a high-stakes backdrop for any technical squeeze momentum.
[https://www.marketbeat.com/stocks/NASDAQ/NFE/short-interest/](https://www.marketbeat.com/stocks/NASDAQ/NFE/short-interest/)
[https://www.nasdaq.com/market-activity/stocks/nfe/short-interest](https://www.nasdaq.com/market-activity/stocks/nfe/short-interest)
[https://www.newfortressenergy.com/operations/offshore-power](https://www.newfortressenergy.com/operations/offshore-power)
https://preview.redd.it/y2zk8ic8ojdg1.jpg?width=1240&format=pjpg&auto=webp&s=13ac99609c402f1f2f86a18cc1fd0a8e659864b6
\-----------------------------------------------------------------------------------------------
# PAVS (Paranovus Entertainment Technology Ltd.):
[https://fintel.io/ss/us/pavs](https://fintel.io/ss/us/pavs)
Short Interest: 241.83% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 55.04% (source: FINRA);
Days to Cover: 0.10.
Additionally, PAVS recently regained compliance with Nasdaq listing requirements, canceling a planned delisting hearing and ensuring continued listing on the Nasdaq Capital Market. The company also achieved a staggering \~18,037% year-over-year revenue growth in the first half of 2025 (reaching $12.4 million in revenue) and even swung to a net profit, showcasing the success of its strategic pivot into e-commerce and AI-driven entertainment.
[https://www.nasdaq.com/market-activity/stocks/pavs/short-interest](https://www.nasdaq.com/market-activity/stocks/pavs/short-interest)
[https://www.globenewswire.com/news-release/2026/01/06/2802332/0/en/Paranovus-Regains-Compliance-with-Nasdaq-Listing-Standards.html](https://www.globenewswire.com/news-release/2026/01/06/2802332/0/en/Paranovus-Regains-Compliance-with-Nasdaq-Listing-Standards.html)
[https://www.sec.gov/ix?doc=/Archives/edgar/data/1761068/000121390025090032/f6k121723\_paranovus.htm](https://www.sec.gov/ix?doc=/Archives/edgar/data/1761068/000121390025090032/f6k121723_paranovus.htm)
https://preview.redd.it/hjnllj99ojdg1.jpg?width=1198&format=pjpg&auto=webp&s=0100895c5b4c2049ca2bfd0daaf4da445d12328c
\-----------------------------------------------------------------------------------------------
# AEHL (Antelope Enterprise Holdings Ltd.):
[https://fintel.io/ss/us/aehl](https://fintel.io/ss/us/aehl)
Interest: 161.24% of float (source: NASDAQ);
ShortOff-Exchange Short Volume Ratio: 57.82% (source: FINRA);
Days to Cover: 7.29.
AEHL secured a strategic financing deal for up to $50 million to be used exclusively for purchasing Bitcoin, signaling a bold pivot that could strengthen its balance sheet and investor confidence. The company plans to roll out a comprehensive long-term Bitcoin strategic roadmap and is actively exploring broader Web3 and crypto-finance initiatives to drive future growth. AEHL’s CEO described this pivot as the "true starting point" of the company’s digital transformation, moving from planning to execution, reflecting management’s confidence that crypto asset holdings can boost the firm’s prospects.
[https://www.nasdaq.com/market-activity/stocks/aehl/short-interest](https://www.nasdaq.com/market-activity/stocks/aehl/short-interest)
[https://www.globenewswire.com/news-release/2025/07/09/2691432/0/en/Antelope-Enterprise-Announces-50-Million-Bitcoin-Financing.html](https://www.globenewswire.com/news-release/2025/07/09/2691432/0/en/Antelope-Enterprise-Announces-50-Million-Bitcoin-Financing.html)
https://preview.redd.it/h97gudvaojdg1.jpg?width=1176&format=pjpg&auto=webp&s=1c61c633b429e9c18a9da4bf56ac4e5c356ccc79
\-----------------------------------------------------------------------------------------------
# WOK (WORK Medical Technology Group Ltd.):
[https://fintel.io/ss/us/wok](https://fintel.io/ss/us/wok)
Short Interest: 4.50% of float (source: NASDAQ);
Days to Cover: 0.10;
Short Borrow Fee Rate: \~117.9%.
WOK’s subsidiary signed an exclusive one-year distribution partnership with Shanghai Benke to promote its AI-driven blood cell analyzer in East China throughout 2026, targeting at least ¥10 million in annual sales. This new AI blood cell analyzer recently obtained Class II medical device manufacturing approval in China, underscoring its readiness for commercial rollout. WORK Medical also boasts a broad portfolio of 21 medical products (15 of which are sold across more than 30 countries, with 17 of its devices registered with the U.S. FDA), providing a strong foundation of credibility and market reach.
[https://www.nasdaq.com/market-activity/stocks/wok/short-interest](https://www.nasdaq.com/market-activity/stocks/wok/short-interest)
https://preview.redd.it/touw1msbojdg1.jpg?width=1621&format=pjpg&auto=webp&s=6a6bb3d9b913ef8242dfc8f00bcfc2e2bc5f3d40
\-----------------------------------------------------------------------------------------------
# RPGL (Republic Power Group Limited):
[https://fintel.io/ss/us/rpgl](https://fintel.io/ss/us/rpgl)
Short Interest: 36.79% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 47.42%(source: FINRA);
Days to Cover: 4.11.
In summary, RPGL has demonstrated improving fundamentals, posting approximately $2.36 million in revenue and $0.28 million in net profit over the last twelve months. As a newly listed company (IPO in October 2025), RPGL has impressively already achieved profitability. It maintains a net cash position as well, its cash on hand exceeds its debt, giving the company a solid financial footing as it expands its customized software development services business.
[https://www.nasdaq.com/market-activity/stocks/rpgl/short-interest](https://www.nasdaq.com/market-activity/stocks/rpgl/short-interest)
https://preview.redd.it/2ttapmmcojdg1.jpg?width=1189&format=pjpg&auto=webp&s=dd1ccd4d797692b592d2de8103031b19b398df00
https://preview.redd.it/9xyvn41fojdg1.png?width=1128&format=png&auto=webp&s=afbdc420be275244aab28d58c1fa754be66e9e9d
\-----------------------------------------------------------------------------------------------
# SUGP (SU Group Holdings Ltd.):
[https://fintel.io/ss/us/sugp](https://fintel.io/ss/us/sugp)
Short Interest: 22.54% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 51.32% (source: FINRA);
Days to Cover: 0.34.
SUGP is a highly insider-controlled company, its Chairman, Mr. Chan Ming Dave, holds about 99% of the voting power after a dual-class share restructuring. The company also secured its largest contract ever, an HK$88.5 million (\~$11.3 million) smart hospital security project in HongKong, with initial revenue expected to be recognized in Q4 2025. Notably, SUGP is essentially debt-free, carrying no meaningful debt on its balance sheet, which gives it greater financial flexibility as it pursues these new projects.
[https://www.nasdaq.com/market-activity/stocks/sugp/short-interest](https://www.nasdaq.com/market-activity/stocks/sugp/short-interest)
https://preview.redd.it/doeeap3gojdg1.jpg?width=1191&format=pjpg&auto=webp&s=ad3e88e4fba552fee7f8319f2b973cdc065767df
\-----------------------------------------------------------------------------------------------
# DRCT (Direct Digital Holdings, Inc.):
[https://fintel.io/ss/us/drct](https://fintel.io/ss/us/drct)
Short Interest: 389.44% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 64.38% (source: FINRA);
Days to Cover: 0.31.
This exceptionally high short interest relative to float places DRCT in extreme squeeze territory, especially as available shares are limited and borrow costs have reportedly trended higher. The off-exchange short activity shows concentrated short positioning in dark pools and alternative venues. Additionally, Direct Digital has posted strong revenue growth in recent quarters driven by its programmatic advertising platform, which continues expanding across underserved multicultural and mid-tier media markets. The company reaffirmed its full-year revenue guidance of $100M+, up significantly from prior years, reflecting robust advertiser demand and margin resilience.
[https://www.nasdaq.com/market-activity/stocks/drct/short-interest](https://www.nasdaq.com/market-activity/stocks/drct/short-interest)

[https://www.marketbeat.com/stocks/NASDAQ/DRCT/short-interest/](https://www.marketbeat.com/stocks/NASDAQ/DRCT/short-interest/)
https://preview.redd.it/6bruyxzlojdg1.png?width=944&format=png&auto=webp&s=1185c319fac092bb35a8952fe1623fd7b797cda2
sentiment 1.00
13 hr ago • u/Your_Answer_Is_No • r/pennystocks • the_lounge • C
What are everyone's thoughts on PAVS? Thinking of getting rid of it, but there's a lot of talk of a high SI. I just don't know if it's reported correctly with the RS recently
sentiment 0.00
15 hr ago • u/Difficult_Winner_777 • r/smallstreetbets • january_2026_squeeze_radar_list • Epic DD Analysis • B
In the spirit of the new year, I wanted to share with everyone a myriad portion of stocks on my radar for squeeze setups. Below I will list them with their respective links and some key details. This is not financial advice, this is just information. Always do your homework, nerds.
I originally posted this on short squeeze but I figured Id try something new.
In this List: DRMA, NFE, PAVS, AEHL, WOK, RPGL, SUGP. DRCT.
\-----------------------------------------------------------------------------------------------
# DRMA (Dermata Therapeutics Inc.):
[https://fintel.io/ss/us/drma](https://fintel.io/ss/us/drma)
Short Interest: 3,604.43% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 53.21% (source: FINRA);
Days to Cover: 8.87.
DRMA announced that its acne treatment XYNGARI achieved highly significant results in a Phase 3 trial, meeting all primary endpoints. Building on this momentum, management noted that the robust Phase 3 results have de-risked the upcoming second Phase 3 trial and position XYNGARI to potentially become the first oncwe-weekly topical acne treatment if approved. The company has also initiated discussions with potential partners for the Phase 3 program and eventual commercial rights to XYNGARI, signaling confidence in bringing this novel therapy to market.This was trailing above 100% just before the Jan12 data dump.
[https://www.nasdaq.com/market-activity/stocks/drma/short-interest](https://www.nasdaq.com/market-activity/stocks/drma/short-interest)
https://preview.redd.it/d30njg25ojdg1.jpg?width=1174&format=pjpg&auto=webp&s=634c324410ddbec3fee0da56970a3ad419c19808
https://preview.redd.it/82t7pvr5ojdg1.jpg?width=987&format=pjpg&auto=webp&s=b70e46779b97c4afe889126052fe5df2e7a51caf
\-----------------------------------------------------------------------------------------------
# NFE (New Fortress Energy Inc.):
[https://fintel.io/ss/us/nfe](https://fintel.io/ss/us/nfe)
Short Interest: 53.81 percent of float (source: NASDAQ)
Off-Exchange Short Volume Ratio: 51.93 percent (source: FINRA)
Days to Cover: 8.80
New Fortress Energy (NFE) is showing an elevated short interest profile with over 69 million shares short and a days-to-cover ratio nearing 9, suggesting shorts could be vulnerable to rapid covering pressure. The stock’s high off-exchange short volume further indicates non-transparent positioning that could unwind under a liquidity crunch. Additionally, NFE has maintained significant global LNG infrastructure exposure and recently secured final agreements for its offshore gas-to-power projects, which are expected to drive meaningful revenue growth over the next several quarters. These strategic expansions support long-term fundamentals while setting up a high-stakes backdrop for any technical squeeze momentum.
[https://www.marketbeat.com/stocks/NASDAQ/NFE/short-interest/](https://www.marketbeat.com/stocks/NASDAQ/NFE/short-interest/)
[https://www.nasdaq.com/market-activity/stocks/nfe/short-interest](https://www.nasdaq.com/market-activity/stocks/nfe/short-interest)
[https://www.newfortressenergy.com/operations/offshore-power](https://www.newfortressenergy.com/operations/offshore-power)
https://preview.redd.it/y2zk8ic8ojdg1.jpg?width=1240&format=pjpg&auto=webp&s=13ac99609c402f1f2f86a18cc1fd0a8e659864b6
\-----------------------------------------------------------------------------------------------
# PAVS (Paranovus Entertainment Technology Ltd.):
[https://fintel.io/ss/us/pavs](https://fintel.io/ss/us/pavs)
Short Interest: 241.83% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 55.04% (source: FINRA);
Days to Cover: 0.10.
Additionally, PAVS recently regained compliance with Nasdaq listing requirements, canceling a planned delisting hearing and ensuring continued listing on the Nasdaq Capital Market. The company also achieved a staggering \~18,037% year-over-year revenue growth in the first half of 2025 (reaching $12.4 million in revenue) and even swung to a net profit, showcasing the success of its strategic pivot into e-commerce and AI-driven entertainment.
[https://www.nasdaq.com/market-activity/stocks/pavs/short-interest](https://www.nasdaq.com/market-activity/stocks/pavs/short-interest)
[https://www.globenewswire.com/news-release/2026/01/06/2802332/0/en/Paranovus-Regains-Compliance-with-Nasdaq-Listing-Standards.html](https://www.globenewswire.com/news-release/2026/01/06/2802332/0/en/Paranovus-Regains-Compliance-with-Nasdaq-Listing-Standards.html)
[https://www.sec.gov/ix?doc=/Archives/edgar/data/1761068/000121390025090032/f6k121723\_paranovus.htm](https://www.sec.gov/ix?doc=/Archives/edgar/data/1761068/000121390025090032/f6k121723_paranovus.htm)
https://preview.redd.it/hjnllj99ojdg1.jpg?width=1198&format=pjpg&auto=webp&s=0100895c5b4c2049ca2bfd0daaf4da445d12328c
\-----------------------------------------------------------------------------------------------
# AEHL (Antelope Enterprise Holdings Ltd.):
[https://fintel.io/ss/us/aehl](https://fintel.io/ss/us/aehl)
Interest: 161.24% of float (source: NASDAQ);
ShortOff-Exchange Short Volume Ratio: 57.82% (source: FINRA);
Days to Cover: 7.29.
AEHL secured a strategic financing deal for up to $50 million to be used exclusively for purchasing Bitcoin, signaling a bold pivot that could strengthen its balance sheet and investor confidence. The company plans to roll out a comprehensive long-term Bitcoin strategic roadmap and is actively exploring broader Web3 and crypto-finance initiatives to drive future growth. AEHL’s CEO described this pivot as the "true starting point" of the company’s digital transformation, moving from planning to execution, reflecting management’s confidence that crypto asset holdings can boost the firm’s prospects.
[https://www.nasdaq.com/market-activity/stocks/aehl/short-interest](https://www.nasdaq.com/market-activity/stocks/aehl/short-interest)
[https://www.globenewswire.com/news-release/2025/07/09/2691432/0/en/Antelope-Enterprise-Announces-50-Million-Bitcoin-Financing.html](https://www.globenewswire.com/news-release/2025/07/09/2691432/0/en/Antelope-Enterprise-Announces-50-Million-Bitcoin-Financing.html)
https://preview.redd.it/h97gudvaojdg1.jpg?width=1176&format=pjpg&auto=webp&s=1c61c633b429e9c18a9da4bf56ac4e5c356ccc79
\-----------------------------------------------------------------------------------------------
# WOK (WORK Medical Technology Group Ltd.):
[https://fintel.io/ss/us/wok](https://fintel.io/ss/us/wok)
Short Interest: 4.50% of float (source: NASDAQ);
Days to Cover: 0.10;
Short Borrow Fee Rate: \~117.9%.
WOK’s subsidiary signed an exclusive one-year distribution partnership with Shanghai Benke to promote its AI-driven blood cell analyzer in East China throughout 2026, targeting at least ¥10 million in annual sales. This new AI blood cell analyzer recently obtained Class II medical device manufacturing approval in China, underscoring its readiness for commercial rollout. WORK Medical also boasts a broad portfolio of 21 medical products (15 of which are sold across more than 30 countries, with 17 of its devices registered with the U.S. FDA), providing a strong foundation of credibility and market reach.
[https://www.nasdaq.com/market-activity/stocks/wok/short-interest](https://www.nasdaq.com/market-activity/stocks/wok/short-interest)
https://preview.redd.it/touw1msbojdg1.jpg?width=1621&format=pjpg&auto=webp&s=6a6bb3d9b913ef8242dfc8f00bcfc2e2bc5f3d40
\-----------------------------------------------------------------------------------------------
# RPGL (Republic Power Group Limited):
[https://fintel.io/ss/us/rpgl](https://fintel.io/ss/us/rpgl)
Short Interest: 36.79% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 47.42%(source: FINRA);
Days to Cover: 4.11.
In summary, RPGL has demonstrated improving fundamentals, posting approximately $2.36 million in revenue and $0.28 million in net profit over the last twelve months. As a newly listed company (IPO in October 2025), RPGL has impressively already achieved profitability. It maintains a net cash position as well, its cash on hand exceeds its debt, giving the company a solid financial footing as it expands its customized software development services business.
[https://www.nasdaq.com/market-activity/stocks/rpgl/short-interest](https://www.nasdaq.com/market-activity/stocks/rpgl/short-interest)
https://preview.redd.it/2ttapmmcojdg1.jpg?width=1189&format=pjpg&auto=webp&s=dd1ccd4d797692b592d2de8103031b19b398df00
https://preview.redd.it/9xyvn41fojdg1.png?width=1128&format=png&auto=webp&s=afbdc420be275244aab28d58c1fa754be66e9e9d
\-----------------------------------------------------------------------------------------------
# SUGP (SU Group Holdings Ltd.):
[https://fintel.io/ss/us/sugp](https://fintel.io/ss/us/sugp)
Short Interest: 22.54% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 51.32% (source: FINRA);
Days to Cover: 0.34.
SUGP is a highly insider-controlled company, its Chairman, Mr. Chan Ming Dave, holds about 99% of the voting power after a dual-class share restructuring. The company also secured its largest contract ever, an HK$88.5 million (\~$11.3 million) smart hospital security project in HongKong, with initial revenue expected to be recognized in Q4 2025. Notably, SUGP is essentially debt-free, carrying no meaningful debt on its balance sheet, which gives it greater financial flexibility as it pursues these new projects.
[https://www.nasdaq.com/market-activity/stocks/sugp/short-interest](https://www.nasdaq.com/market-activity/stocks/sugp/short-interest)
https://preview.redd.it/doeeap3gojdg1.jpg?width=1191&format=pjpg&auto=webp&s=ad3e88e4fba552fee7f8319f2b973cdc065767df
\-----------------------------------------------------------------------------------------------
# DRCT (Direct Digital Holdings, Inc.):
[https://fintel.io/ss/us/drct](https://fintel.io/ss/us/drct)
Short Interest: 389.44% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 64.38% (source: FINRA);
Days to Cover: 0.31.
This exceptionally high short interest relative to float places DRCT in extreme squeeze territory, especially as available shares are limited and borrow costs have reportedly trended higher. The off-exchange short activity shows concentrated short positioning in dark pools and alternative venues. Additionally, Direct Digital has posted strong revenue growth in recent quarters driven by its programmatic advertising platform, which continues expanding across underserved multicultural and mid-tier media markets. The company reaffirmed its full-year revenue guidance of $100M+, up significantly from prior years, reflecting robust advertiser demand and margin resilience.
[https://www.nasdaq.com/market-activity/stocks/drct/short-interest](https://www.nasdaq.com/market-activity/stocks/drct/short-interest)

[https://www.marketbeat.com/stocks/NASDAQ/DRCT/short-interest/](https://www.marketbeat.com/stocks/NASDAQ/DRCT/short-interest/)
https://preview.redd.it/6bruyxzlojdg1.png?width=944&format=png&auto=webp&s=1185c319fac092bb35a8952fe1623fd7b797cda2
sentiment 1.00
2 days ago • u/Difficult_Winner_777 • r/Shortsqueeze • january_2026_squeeze_radar_list • C
CTB on PAVS is rising.
https://preview.redd.it/3it0a0ngmcdg1.jpeg?width=1080&format=pjpg&auto=webp&s=748145c008e2aa4d4754ad581c5b01c835360ad3
[https://fintel.io/ss/us/pavs](https://fintel.io/ss/us/pavs)
sentiment 0.00
2 days ago • u/Difficult_Winner_777 • r/Shortsqueeze • january_2026_squeeze_radar_list • 💣NEW Fucking Squeeze Play • B
In the spirit of the new year, I wanted to share with everyone a myriad portion of stocks on my radar for squeeze setups. Below I will list them with
their respective links and some key details. This is not financial
advice, this is just information. Always do your homework, nerds.
In this List: DRMA, NFE, PAVS, AEHL, WOK, RPGL, SUGP
\-----------------------------------------------------------------------------------------------
# DRMA (Dermata Therapeutics Inc.):
[https://fintel.io/ss/us/drma](https://fintel.io/ss/us/drma)
Short Interest: 3,604.43% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 53.21% (source: FINRA);
Days to Cover: 8.87.
DRMA announced that its acne treatment XYNGARI achieved highly significant results in a Phase 3 trial, meeting all primary endpoints. Building on this momentum, management noted that the robust Phase 3 results have de-risked the upcoming second Phase 3 trial and position XYNGARI to potentially become the first oncwe-weekly topical acne treatment if approved. The company has also initiated discussions with potential partners for the Phase 3 program and eventual commercial rights to XYNGARI, signaling confidence in bringing this novel therapy to market.
This was trailing above 100% just before the Jan12 data dump.
[https://www.nasdaq.com/market-activity/stocks/drma/short-interest](https://www.nasdaq.com/market-activity/stocks/drma/short-interest)
[https://www.dermatarx.com/news-media/press-releases/detail/128/dermata-announces-positive-topline-results-for-its](https://www.dermatarx.com/news-media/press-releases/detail/128/dermata-announces-positive-topline-results-for-its)
[https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000141057825002308/drma-20250930x10q.htm](https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000141057825002308/drma-20250930x10q.htm)
https://preview.redd.it/qjkuukq3pbdg1.png?width=1174&format=png&auto=webp&s=124f16a43b38337c5d7fc39b3806d9d6ed0e577c
https://preview.redd.it/1006dlh4pbdg1.png?width=987&format=png&auto=webp&s=c32618aa050d5277b92c2f90ee4d3c2471c3b8a5
\-----------------------------------------------------------------------------------------------
# NFE (New Fortress Energy Inc.):
[https://fintel.io/ss/us/nfe](https://fintel.io/ss/us/nfe)
Short Interest: 53.81 percent of float (source: NASDAQ)
Off-Exchange Short Volume Ratio: 51.93 percent (source: FINRA)
Days to Cover: 8.80
New Fortress Energy (NFE) is showing an elevated short interest profile with over 69 million shares short and a days-to-cover ratio nearing 9, suggesting shorts could be vulnerable to rapid covering pressure. The stock’s high off-exchange short volume further indicates non-transparent positioning that could unwind under a liquidity crunch. Additionally, NFE has maintained significant global LNG infrastructure exposure and recently secured final agreements for its offshore gas-to-power projects, which are expected to drive meaningful revenue growth over the next several quarters. These strategic expansions support long-term fundamentals while setting up a high-stakes backdrop for any technical squeeze momentum.
Source URLs:
[https://www.marketbeat.com/stocks/NASDAQ/NFE/short-interest/](https://www.marketbeat.com/stocks/NASDAQ/NFE/short-interest/)
[https://www.nasdaq.com/market-activity/stocks/nfe/short-interest](https://www.nasdaq.com/market-activity/stocks/nfe/short-interest)
[https://www.newfortressenergy.com/operations/offshore-power](https://www.newfortressenergy.com/operations/offshore-power)
https://preview.redd.it/nv3jazo5pbdg1.png?width=1240&format=png&auto=webp&s=7fdcaf3fa248b05edb0cad672489b2a478e2c504
\-----------------------------------------------------------------------------------------------
# PAVS (Paranovus Entertainment Technology Ltd.):
[https://fintel.io/ss/us/pavs](https://fintel.io/ss/us/pavs)
Short Interest: 241.83% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 55.04% (source: FINRA);
Days to Cover: 0.10.
Additionally, PAVS recently regained compliance with Nasdaq listing requirements, canceling a planned delisting hearing and ensuring continued listing on the Nasdaq Capital Market. The company also achieved a staggering \~18,037% year-over-year revenue growth in the first half of 2025 (reaching $12.4 million in revenue) and even swung to a net profit, showcasing the success of its strategic pivot into e-commerce and AI-driven entertainment.https://www.nasdaq.com/market-activity/stocks/pavs/short-interest
[https://www.globenewswire.com/news-release/2026/01/06/2802332/0/en/Paranovus-Regains-Compliance-with-Nasdaq-Listing-Standards.html](https://www.globenewswire.com/news-release/2026/01/06/2802332/0/en/Paranovus-Regains-Compliance-with-Nasdaq-Listing-Standards.html)
[https://www.sec.gov/ix?doc=/Archives/edgar/data/1761068/000121390025090032/f6k121723\_paranovus.htm](https://www.sec.gov/ix?doc=/Archives/edgar/data/1761068/000121390025090032/f6k121723_paranovus.htm)
https://preview.redd.it/b4sko6j8pbdg1.png?width=1198&format=png&auto=webp&s=074b2ee4b5fe564a7badd4cfdf8fff483d168f8b
\-----------------------------------------------------------------------------------------------
# AEHL (Antelope Enterprise Holdings Ltd.):
[https://fintel.io/ss/us/aehl](https://fintel.io/ss/us/aehl)
Short Interest: 161.24% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 57.82% (source: FINRA);
Days to Cover: 7.29.
AEHL secured a strategic financing deal for up to $50 million to be used exclusively for purchasing Bitcoin, signaling a bold pivot that could strengthen its balance sheet and investor confidence. The company plans to roll out a comprehensive long-term Bitcoin strategic roadmap and is actively exploring broader Web3 and crypto-finance initiatives to drive future growth. AEHL’s CEO described this pivot as the "true starting point" of the company’s digital transformation, moving from planning to execution, reflecting management’s confidence that crypto asset holdings can boost the firm’s prospects.https://www.nasdaq.com/market-activity/stocks/aehl/short-interest
[https://www.globenewswire.com/news-release/2025/07/09/2691432/0/en/Antelope-Enterprise-Announces-50-Million-Bitcoin-Financing.html](https://www.globenewswire.com/news-release/2025/07/09/2691432/0/en/Antelope-Enterprise-Announces-50-Million-Bitcoin-Financing.html)
https://preview.redd.it/uq2m5nwapbdg1.png?width=1176&format=png&auto=webp&s=6717dbbeed80d79c200c1f8c0fef8f6e176654dc
\-----------------------------------------------------------------------------------------------
# WOK (WORK Medical Technology Group Ltd.):
[https://fintel.io/ss/us/wok](https://fintel.io/ss/us/wok)
Short Interest: 4.50% of float (source: NASDAQ);
Days to Cover: 0.10;
Short Borrow Fee Rate: \~117.9%.
WOK’s subsidiary signed an exclusive one-year distribution partnership with Shanghai Benke to promote its AI-driven blood cell analyzer in East China throughout 2026, targeting at least ¥10 million in annual sales. This new AI blood cell analyzer recently obtained Class II medical device manufacturing approval in China, underscoring its readiness for commercial rollout. WORK Medical also boasts a broad portfolio of 21 medical products (15 of which are sold across more than 30 countries, with 17 of its devices registered with the U.S. FDA), providing a strong foundation of credibility and market reach.https://www.nasdaq.com/market-activity/stocks/wok/short-interest
[https://www.sec.gov/Archives/edgar/data/1929783/000121390025091998/ea0258889-424b5\_workmed.htm](https://www.sec.gov/Archives/edgar/data/1929783/000121390025091998/ea0258889-424b5_workmed.htm)
[https://www.workmedtech.com/news/ai-analyzer-approval-pr](https://www.workmedtech.com/news/ai-analyzer-approval-pr)
https://preview.redd.it/i8ev7evbpbdg1.png?width=1621&format=png&auto=webp&s=6c2d66ac24fe48be3ef53319797098f6e257e444
\-----------------------------------------------------------------------------------------------
# RPGL (Republic Power Group Limited):
[https://fintel.io/ss/us/rpgl](https://fintel.io/ss/us/rpgl)
Short Interest: 36.79% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 47.42%(source: FINRA);
Days to Cover: 4.11.
In summary, RPGL has demonstrated improving fundamentals, posting approximately $2.36 million in revenue and $0.28 million in net profit over the last twelve months. As a newly listed company (IPO in October 2025), RPGL has impressively already achieved profitability. It maintains a net cash position as well, its cash on hand exceeds its debt, giving the company a solid financial footing as it expands its customized software development services business.https://www.nasdaq.com/market-activity/stocks/rpgl/short-interest
[https://www.sec.gov/Archives/edgar/data/2007559/000121390026000868/ea0232443-6k\_republic.htm](https://www.sec.gov/Archives/edgar/data/2007559/000121390026000868/ea0232443-6k_republic.htm)
[https://www.marketwatch.com/investing/stock/rpgl](https://www.marketwatch.com/investing/stock/rpgl)
https://preview.redd.it/ae3r0h5epbdg1.png?width=1189&format=png&auto=webp&s=93a506c7e2488657d7b663d7c5b4cbe91caee984
\-----------------------------------------------------------------------------------------------
# SUGP (SU Group Holdings Ltd.):
[https://fintel.io/ss/us/sugp](https://fintel.io/ss/us/sugp)
Short Interest: 22.54% of float (source: NASDAQ);
Off-Exchange Short Volume Ratio: 51.32% (source: FINRA);
Days to Cover: 0.34.
SUGP is a highly insider-controlled company, its Chairman, Mr. Chan Ming Dave, holds about 99% of the voting power after a dual-class share restructuring. The company also secured its largest contract ever, an HK$88.5 million (\~$11.3 million) smart hospital security project in HongKong, with initial revenue expected to be recognized in Q4 2025. Notably, SUGP is essentially debt-free, carrying no meaningful debt on its balance sheet, which gives it greater financial flexibility as it pursues these new projects.https://www.nasdaq.com/market-activity/stocks/sugp/short-interest
[https://www.sec.gov/Archives/edgar/data/1983136/000121390025045454/ea018528ex99-2\_sugroup.htm](https://www.sec.gov/Archives/edgar/data/1983136/000121390025045454/ea018528ex99-2_sugroup.htm)
[https://www.marketwatch.com/investing/stock/sugp](https://www.marketwatch.com/investing/stock/sugp)
https://preview.redd.it/j4aj9wripbdg1.png?width=1191&format=png&auto=webp&s=ca23ea4044673de4bd97b0a0448044a72c77d7c0
sentiment 1.00


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC